Theralase Technologies (CVE:TLT) Trading 3.5% Higher – Time to Buy?

Theralase Technologies Inc. (CVE:TLT) shares shot up 3.5% during mid-day trading on Tuesday . The stock traded as high as C$0.30 and last traded at C$0.30. 81,515 shares traded hands during trading, a decline of 23% from the average session volume of 105,486 shares. The stock had previously closed at C$0.29.

Theralase Technologies Trading Up 3.5 %

The company has a market capitalization of C$71.83 million, a price-to-earnings ratio of -15.71 and a beta of 1.36. The company has a debt-to-equity ratio of 14.85, a quick ratio of 3.40 and a current ratio of 1.91. The firm has a fifty day moving average price of C$0.27 and a 200-day moving average price of C$0.24.

Theralase Technologies Company Profile

Theralase Technologies Inc, a clinical stage pharmaceutical company, engages in the research and development of light activated photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions.